Current status of autologous hematopoietic stem cell transplantation in myeloma

Bone Marrow Transplantation

Volumn 42, Issue SUPPL.1, 2008, Pages

  Mehta, J ^a   Singhal, S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA2B INTERFERON; BORTEZOMIB; CARMUSTINE; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; THALIDOMIDE; VINCRISTINE; VINCRISTINE SULFATE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 50549085558     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.109     Document Type: Review

References (47)

1. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822-824.
2. Singhal S. High-dose therapy and autologous transplantation. In: Mehta J, Singhal S (eds). Myeloma, Martin Dunitz: London, 2002, pp 327-347.
3. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
4. Sirohi B, Powles R, Mehta J, Rudin C, Kulkarni S, Horton C et al. An elective single autograft with high-dose melphalan: Single-center study of 451 patients. Bone Marrow Transplant 2005; 36: 19-24.
5. Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 1101-1114.
6. Powles R, Sirohi B, Treleaven J, Singhal S, Kulkarni S, Lal R et al Continued first complete remission in multiple myeloma for over 10 years: A series of 'operationally cured' patients. Blood (ASH Annual Meeting Abstracts) 2000; 96: Abstract 2215.
7. Powles R, Singhal S, Sirohi B, Horton C, Treleaven J, Mehta J. 'Discontinuous complete remission': A new endpoint to evaluate the success of therapy in keeping myeloma patients disease-free for extended periods of timie. Blood (ASH Annual Meeting Abstracts) 2001; 98 166a.
8. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158-164.
9. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al Age is not a prognostic variable with autotransplants multiple myeloma. Blood 1999; 93: 51-54.
10. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533-539.
11. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. N Engl J Med 1996; 335: 91-97.
12. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
13. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: Results of a randomized controlled trial. Blood 2004; 104: 3052-3057.
14. Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755-3759.
15. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55-65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-9233.
16. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997; 20: 435-443.
17. Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 2000; 25: 483-487.
18. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002; 99: 731-735.
19. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
20. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936.
21. Singhal S. Treatment of multiple myeloma. BMJ 2003; 327: 575-576.
22. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
23. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
24. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434-2441.
25. Fermand JP. MAG studies (1985-2005). 10th International Myeloma Workshop, Sydney, April 2005 Accessed 2 December 2006. http://myeloma.org/pdfs/Sydney2005_Fermand_P8.pdf.
26. Goldschmidt H. Single vs double HDT in multiple myeloma:n third analysis of the trial GMMG-HD2. 10th International Myeloma Workshop, Sydney, April 2005. Accessed 2 December 2006. http://myeloma.org/pdfs/ Sydney2005_Goldschmidt_P8.pdf.
27. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood 2003; 101: 2144-2151.
28. Sonneveld P, van der Holt B, Vellenga E, Croockewit S, Verhoef G, Segeren C et al. Intensive versus double intensive therapy in untreated multiple myeloma: Final analysis of the HOVON 24 trial. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 2545.
29. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D et al Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887-892.
30. Sirohi B, Powles R, Mehta J, Kulkarni S, Sankpal S, Treleaven J et al Prognostic factors at the time of single autotransplantation in 451 myeloma patients treated with 200mg/m2 melphalan: Results equivalent to tadem autotransplantation. Blood (ASH Annual Meeting Abstracts) 2002; 100: Abstract 673.
31. Singhal S, Powles R. Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673-679.
32. Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S et al Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: The first step towards on 'operational cure'? Bone Marrow Transplant 2002; 30: 479-484.
33. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. Single agnent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004; 34: 485-490.
34. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
35. Singhal S, Mehta J. Multiple myeloma. Clin J Am Soc Nephrol 2006; 1: 1322-1330.
36. Kumar S, Lacy MQ, Dispenzieri A, Hayman SR, Rajkumar SV, Zeldenrust S et al. Analysis of outcome after autologous stem transplantation in patients with newly diagnosed myeloma: Comparison of different induction regimens. Blood (ASH Annual Meeting Abstracts) 2006; 108: Abstract 3079.
37. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
38. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Haematol 1998; 102: 495-502.
39. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
40. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-3294.
41. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
42. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659-2666.
43. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
44. Crowley JJ, McCoy J, LeBlanc M, Barlogie B. Extreme regression: A statistical technique for finding good or poor prognostic groups, illustrated using myeloma patient data from intergroup trial S9321. Blood (ASH Annual Meeting Abstracts) 2004; 102: Abstract 5202.
45. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
46. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Enyl J Med 2003; 348: 2609-2617.
47. Singhal S, Mehta J. Lenalidomide in myeloma. Curr Treatment Options Oncol 2007; 8: 154-163.